Praxis Precision Medicines/$PRAX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Praxis Precision Medicines
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
- Ticker
- $PRAX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 168
- Headquarters
- Boston, United States
- Website
- praxismedicines.com
PRAX Metrics
BasicAdvanced
$8.3B
-
-$12.86
2.78
-
Price and volume
Market cap
$8.3B
Beta
2.78
52-week high
$392.70
52-week low
$50.31
Average daily volume
411K
Financial strength
Current ratio
15.734
Quick ratio
15.462
Long term debt to equity
0.001
Total debt to equity
0.001
Profitability
EBITDA (TTM)
-378.048
Management effectiveness
Return on assets (TTM)
-25.65%
Return on equity (TTM)
-38.86%
Valuation
Price to book
6.15
Price to tangible book (TTM)
6.15
Price to free cash flow (TTM)
-25.458
Free cash flow yield (TTM)
-3.93%
Free cash flow per share (TTM)
-11.608
Growth
Earnings per share change (TTM)
4.28%
3-year earnings per share growth (CAGR)
-33.39%
What the Analysts think about PRAX
Analyst ratings (Buy, Hold, Sell) for Praxis Precision Medicines stock.
Analyst projections of the future price of Praxis Precision Medicines stock.
Bulls say / Bears say
Ulixacaltamide gives Praxis a near-term route into essential tremor, a large underserved market: its Phase 3 programme was positive, and the FDA’s review had raised no major safety or efficacy concerns by August. The agency was not planning an advisory committee meeting, with a decision due by January 2027. (GlobeNewswire)
Relutrigine could address severe SCN2A- and SCN8A-related epilepsies with no approved treatment for those genetic forms. In the registrational study, it delivered a 53% placebo-adjusted reduction in motor seizures, giving the application meaningful clinical support despite the extended FDA review. (NeurologyLive)
Praxis has further upside beyond its two pending drug applications: elsunersen received FDA Breakthrough Therapy designation after positive early trial results in SCN2A-related epilepsy. That offers another potential development path if later studies confirm the early findings. (GlobeNewswire)
The FDA extended relutrigine’s review by three months after treating additional analyses of existing clinical data as a major amendment. No new studies or safety concerns were cited, but the delay leaves the application exposed to further regulatory uncertainty. (GlobeNewswire)
Vormatrigine failed to meet POWER1’s primary endpoint for reducing focal seizures, and Praxis paused enrolment in a second study while reassessing the programme. This weakens the value of a pipeline asset that had been expected to broaden the company’s epilepsy opportunity. (Endpoints News)
Praxis is still pre-commercial and reported a $176.3 million net loss for the first half of 2026 as it expanded research and launch spending. A delay to approvals or slower uptake would leave it consuming cash before product sales can help fund the business. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2026.
PRAX Financial Performance
Revenues and expenses
PRAX Earnings Performance
Company profitability
Upcoming events
No upcoming events
PRAX News
AllArticlesVideos
Funds containing PRAX
AllUSDGBPEUR
Fund name | Fund size | $PRAX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.56% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.56% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.24% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.24% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.